FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jose Luis Manzano

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Genes & Molecular Sequences

Genes, ras

Co-author Network

Publications

TOP 3
Eva Martinez-Balibrea; Albert Abad; A Martínez-Cardús; A Ginés; M Valladares; M Navarro; Enrique Aranda; E Marcuello; M Benavides; B Massutí; A Carrato; L Layos; Jose Luis Manzano; V Moreno
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Albert Font; Ramon Salazar; Joan Maurel; Miquel Taron; Jose Luis Ramirez; Josep Tabernero; Rosa Gallego; Esther Casado; Jose Luis Manzano; Enric Carcereny; Marta Guix; Jaume Fernández-Llamazares; Rafael Rosell
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Albert Font; A Arellano; Jaume Fernández-Llamazares; D Casas; J Boix; J Cardenal; Mireia Margelí; Jose Luis Manzano; Albert Abad; Rafael Rosell
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jose Luis Manzano (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Eva Martinez-Balibrea; Albert Abad; A Martínez-Cardús; A Ginés; M Valladares; M Navarro; Enrique Aranda; E Marcuello; M Benavides; B Massutí; A Carrato; L Layos; Jose Luis Manzano; V Moreno
UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
British journal of cancer 2010;103(4):581-9.
2008: Albert Font; Ramon Salazar; Joan Maurel; Miquel Taron; Jose Luis Ramirez; Josep Tabernero; Rosa Gallego; Esther Casado; Jose Luis Manzano; Enric Carcereny; Marta Guix; Jaume Fernández-Llamazares; Rafael Rosell
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Cancer chemotherapy and pharmacology 2008;62(6):1075-83.
2007: Albert Font; A Arellano; Jaume Fernández-Llamazares; D Casas; J Boix; J Cardenal; Mireia Margelí; Jose Luis Manzano; Albert Abad; Rafael Rosell
Weekly docetaxel with concomitant radiotherapy in patients with inoperable oesophageal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2007;9(3):177-82.
2007: Eva Martinez-Balibrea; Jose Luis Manzano; Anna Martinez-Cardus; Teresa Moran; Beatriz Cirauqui; Silvia Catot; Miquel Taron; Albert Abad
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan.
Oncology reports 2007;17(3):637-45.
2003: Albert Font; José Miguel Sánchez; Miquel Tarón; Eva Martinez-Balibrea; José Javier Sánchez; Jose Luis Manzano; Mireia Margelí; Martin Richardet; Agustí Barnadas; Albert Abad; Rafael Rosell
Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
Investigational new drugs 2003;21(4):435-43.
2003: C Balaña; Jose Luis Manzano; I Moreno; Beatriz Cirauqui; Albert Abad; Albert Font; José-Luis Mate; Rafael Rosell
A phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(9):1425-9.
2003: José Luis Ramirez; Carme Sarries; Pedro Lopez de Castro; Barbara Roig; Cristina Queralt; Daniel Escuin; Itziar de Aguirre; Jose Miguel Sanchez; Jose Luis Manzano; Mireia Margelí; Jose Javier Sanchez; Julio Astudillo; Miquel Taron; Rafael Rosell
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.
Cancer letters 2003;193(2):207-16.
2002: José Miguel Sánchez; Carme Balañá; Albert Font; José Javier Sánchez; Jose Luis Manzano; Mónica Guillot; Mireia Margelí; Martin Richardet; Rafael Rosell
Phase II non-randomized study of three different sequences of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2002;38(3):309-15.
2002: Albert Font; Jose Miguel Sanchez; Rafael Rosell; Miquel Taron; E Martinez; Mónica Guillot; Jose Luis Manzano; M Margeli; Agustí Barnadas; Albert Abad
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Lung cancer (Amsterdam, Netherlands) 2002;37(2):213-8.
2002: Rafael Rosell; Mariano Monzó; Vicente Alberola; Miquel Taron; Agustí Barnadas; José Miguel Sánchez; Jose Luis Manzano; Jose Javier Sanchez
Determinants of response and resistance to cytotoxics.
Seminars in oncology 2002;29(1 Suppl 4):110-8.
2001: Rafael Rosell; Enriqueta Felip; Jose Maestre; Jose Miguel Sanchez; Jose Javier Sanchez; Jose Luis Manzano; Julio Astudillo; Miquel Taron; Mariano Monzo
The role of chemotherapy in early non-small-cell lung cancer management.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S63-74.
2001: Albert Font; A Abad; Mariano Monzó; Jose Javier Sanchez; M Guillot; Jose Luis Manzano; M Piñol; I Ojanguren; Rafael Rosell
Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer.
Diseases of the colon and rectum 2001;44(4):549-57.